Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors

Cell Reports

Volumn 20, Issue 11, 2017, Pages 2639-2653

  Baeumler, Toni A ^a   Ahmed, Ahmed Ashour ^a   Fulga, Tudor A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

chimeric receptors; CRISPR; dCas9 synR; dCas9 VP64; genome engineering; GPCR; RTK; split Cas9; synthetic receptors; transcriptional programs

Indexed keywords

ARTIFICIAL RECEPTOR; G PROTEIN COUPLED RECEPTOR; PEPTIDE HYDROLASE; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CELL ENGINEERING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; INCUBATION TIME; LIMIT OF QUANTITATION; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL MEMBRANE; CRISPR CAS SYSTEM; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; TRANSCRIPTION INITIATION;

CELL MEMBRANE; CRISPR-CAS SYSTEMS; GENE EXPRESSION; GENETIC ENGINEERING; HEK293 CELLS; HUMANS; MODELS, BIOLOGICAL; PEPTIDE HYDROLASES; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 85029363645     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.08.044     Document Type: Article

References (57)

1. Balkwill, F., Tumour necrosis factor and cancer. Nat. Rev. Cancer 9 (2009), 361–371.
2. Banaszynski, L.A., Liu, C.W., Wandless, T.J., Characterization of the FKBP.rapamycin.FRB ternary complex. J. Am. Chem. Soc. 127 (2005), 4715–4721.
3. Barnea, G., Strapps, W., Herrada, G., Berman, Y., Ong, J., Kloss, B., Axel, R., Lee, K.J., The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. USA 105 (2008), 64–69.
4. Burton, E.R., Libutti, S.K., Targeting TNF-alpha for cancer therapy. J. Biol., 8, 2009, 85.
5. Chavez, A., Tuttle, M., Pruitt, B.W., Ewen-Campen, B., Chari, R., Ter-Ovanesyan, D., Haque, S.J., Cecchi, R.J., Kowal, E.J.K., Buchthal, J., et al. Comparison of Cas9 activators in multiple species. Nat. Methods 13 (2016), 563–567.
6. Conklin, B.R., Hsiao, E.C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J.R., Guettier, J.M., Chang, W.C., Pei, Y., McCarthy, K.D., et al. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 5 (2008), 673–678.
7. Dominguez, A.A., Lim, W.A., Qi, L.S., Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 17 (2016), 5–15.
8. Dorsam, R.T., Gutkind, J.S., G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7 (2007), 79–94.
9. Farzadfard, F., Perli, S.D., Lu, T.K., Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. ACS Synth. Biol. 2 (2013), 604–613.
10. Ferry, Q.R., Lyutova, R., Fulga, T.A., Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs. Nat. Commun., 8, 2017, 14633.
11. Fesnak, A.D., June, C.H., Levine, B.L., Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16 (2016), 566–581.
12. Gao, Y., Xiong, X., Wong, S., Charles, E.J., Lim, W.A., Qi, L.S., Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat. Methods 13 (2016), 1043–1049.
13. Gill, S., June, C.H., Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263 (2015), 68–89.
14. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
15. Inagaki, H.K., Ben-Tabou de-Leon, S., Wong, A.M., Jagadish, S., Ishimoto, H., Barnea, G., Kitamoto, T., Axel, R., Anderson, D.J., Visualizing neuromodulation in vivo: TANGO-mapping of dopamine signaling reveals appetite control of sugar sensing. Cell 148 (2012), 583–595.
16. Iwamoto, M., Björklund, T., Lundberg, C., Kirik, D., Wandless, T.J., A general chemical method to regulate protein stability in the mammalian central nervous system. Chem. Biol. 17 (2010), 981–988.
17. Jusiak, B., Cleto, S., Perez-Piñera, P., Lu, T.K., Engineering synthetic gene circuits in living cells with CRISPR technology. Trends Biotechnol. 34 (2016), 535–547.
18. Kaur, S., Martin-Manso, G., Pendrak, M.L., Garfield, S.H., Isenberg, J.S., Roberts, D.D., Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 285 (2010), 38923–38932.
19. Kershaw, M.H., Westwood, J.A., Darcy, P.K., Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13 (2013), 525–541.
20. Konermann, S., Brigham, M.D., Trevino, A.E., Joung, J., Abudayyeh, O.O., Barcena, C., Hsu, P.D., Habib, N., Gootenberg, J.S., Nishimasu, H., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517 (2015), 583–588.
21. Kroeze, W.K., Sheffler, D.J., Roth, B.L., G-protein-coupled receptors at a glance. J. Cell Sci. 116 (2003), 4867–4869.
22. Kroeze, W.K., Sassano, M.F., Huang, X.P., Lansu, K., McCorvy, J.D., Giguère, P.M., Sciaky, N., Roth, B.L., PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22 (2015), 362–369.
23. Lawler, P.R., Lawler, J., Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med., 2, 2012, a006627.
24. Lee, D., Creed, M., Jung, K., Stefanelli, T., Wendler, D.J., Oh, W.C., Mignocchi, N.L., Lüscher, C., Kwon, H.B., Temporally precise labeling and control of neuromodulatory circuits in the mammalian brain. Nat. Methods 14 (2017), 495–503.
25. Lemmon, M.A., Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 141 (2010), 1117–1134.
26. Lienert, F., Lohmueller, J.J., Garg, A., Silver, P.A., Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat. Rev. Mol. Cell Biol. 15 (2014), 95–107.
27. Lim, W.A., Designing customized cell signalling circuits. Nat. Rev. Mol. Cell Biol. 11 (2010), 393–403.
28. Lim, W.A., June, C.H., The Principles of Engineering Immune Cells to Treat Cancer. Cell 168 (2017), 724–740.
29. Lim, W., Mayer, B., Pawson, T., Cell Signaling: Principles and Mechanisms. 2014, Science.
30. Liu, Y., Zhan, Y., Chen, Z., He, A., Li, J., Wu, H., Liu, L., Zhuang, C., Lin, J., Guo, X., et al. Directing cellular information flow via CRISPR signal conductors. Nat. Methods 13 (2016), 938–944.
31. Maji, B., Moore, C.L., Zetsche, B., Volz, S.E., Zhang, F., Shoulders, M.D., Choudhary, A., Multidimensional chemical control of CRISPR-Cas9. Nat. Chem. Biol. 13 (2017), 9–11.
32. Mauceri, H.J., Seetharam, S., Beckett, M.A., Lee, J.Y., Gupta, V.K., Gately, S., Stack, M.S., Brown, C.K., Swedberg, K., Kufe, D.W., Weichselbaum, R.R., Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int. J. Cancer 97 (2002), 410–415.
33. Mills, G.B., Moolenaar, W.H., The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3 (2003), 582–591.
34. Morsut, L., Roybal, K.T., Xiong, X., Gordley, R.M., Coyle, S.M., Thomson, M., Lim, W.A., Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164 (2016), 780–791.
35. Nguyen, D.P., Miyaoka, Y., Gilbert, L.A., Mayerl, S.J., Lee, B.H., Weissman, J.S., Conklin, B.R., Wells, J.A., Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity. Nat. Commun., 7, 2016, 12009.
36. Nie, Y., Vigues, S., Hobbs, J.R., Conn, G.L., Munger, S.D., Distinct contributions of T1R2 and T1R3 taste receptor subunits to the detection of sweet stimuli. Curr. Biol. 15 (2005), 1948–1952.
37. Nihongaki, Y., Kawano, F., Nakajima, T., Sato, M., Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat. Biotechnol. 33 (2015), 755–760.
38. Nishi, M., Nanjo, K., Insulin gene mutations and diabetes. J. Diabetes Investig. 2 (2011), 92–100.
39. Nissim, L., Perli, S.D., Fridkin, A., Perez-Pinera, P., Lu, T.K., Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol. Cell 54 (2014), 698–710.
40. Oakes, B.L., Nadler, D.C., Flamholz, A., Fellmann, C., Staahl, B.T., Doudna, J.A., Savage, D.F., Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch. Nat. Biotechnol. 34 (2016), 646–651.
41. Olsson, A.K., Dimberg, A., Kreuger, J., Claesson-Welsh, L., VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7 (2006), 359–371.
42. Pierce, K.L., Premont, R.T., Lefkowitz, R.J., Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002), 639–650.
43. Reiter, E., Lefkowitz, R.J., GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17 (2006), 159–165.
44. Roybal, K.T., Rupp, L.J., Morsut, L., Walker, W.J., McNally, K.A., Park, J.S., Lim, W.A., Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164 (2016), 770–779.
45. Roybal, K.T., Williams, J.Z., Morsut, L., Rupp, L.J., Kolinko, I., Choe, J.H., Walker, W.J., McNally, K.A., Lim, W.A., Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167 (2016), 419–432.
46. Sarabipour, S., Ballmer-Hofer, K., Hristova, K., VEGFR-2 conformational switch in response to ligand binding. eLife, 5, 2016, e13876.
47. Schwarz, K.A., Daringer, N.M., Dolberg, T.B., Leonard, J.N., Rewiring human cellular input-output using modular extracellular sensors. Nat. Chem. Biol. 13 (2017), 202–209.
48. Simons, M., Gordon, E., Claesson-Welsh, L., Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17 (2016), 611–625.
49. Srivastava, S., Riddell, S.R., Engineering CAR-T cells: design concepts. Trends Immunol. 36 (2015), 494–502.
50. Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 (2016), 2123–2138.
51. Wang, W., Wildes, C.P., Pattarabanjird, T., Sanchez, M.I., Glober, G.F., Matthews, G.A., Tye, K.M., Ting, A.Y., A light- and calcium-gated transcription factor for imaging and manipulating activated neurons. Nat. Biotechnol., 2017, 10.1038/nbt.3909 Published online June 26, 2017.
52. Wehr, M.C., Laage, R., Bolz, U., Fischer, T.M., Grünewald, S., Scheek, S., Bach, A., Nave, K.A., Rossner, M.J., Monitoring regulated protein-protein interactions using split TEV. Nat. Methods 3 (2006), 985–993.
53. Wright, A.V., Sternberg, S.H., Taylor, D.W., Staahl, B.T., Bardales, J.A., Kornfeld, J.E., Doudna, J.A., Rational design of a split-Cas9 enzyme complex. Proc. Natl. Acad. Sci. USA 112 (2015), 2984–2989.
54. Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R., Benenson, Y., Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 333 (2011), 1307–1311.
55. Xie, M., Ye, H., Wang, H., Charpin-El Hamri, G., Lormeau, C., Saxena, P., Stelling, J., Fussenegger, M., β-cell-mimetic designer cells provide closed-loop glycemic control. Science 354 (2016), 1296–1301.
56. Zalatan, J.G., Lee, M.E., Almeida, R., Gilbert, L.A., Whitehead, E.H., La Russa, M., Tsai, J.C., Weissman, J.S., Dueber, J.E., Qi, L.S., Lim, W.A., Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160 (2015), 339–350.
57. Zetsche, B., Volz, S.E., Zhang, F., A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33 (2015), 139–142.